Macrophages in Tumor Microenvironments and the Progression of Tumors
Open accessThe DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Macrophages are widely distributed innate immune cells that play indispensable roles in the innate and adaptive immune response to pathogens and in-tissue homeostasis. Macrophages can be activated by a variety of stimuli and polarized to functionally different phenotypes. Two distinct subsets of macrophages have been proposed, including classically activated (M1) and alternatively activated (M2) macrophages. M1 macrophages express a series of proinflammatory cytokines, chemokines, and effector molecules, such as IL-12, IL-23, TNF-α, iNOS and MHCI/II. In contrast, M2 macrophages express a wide array of anti-inflammatory molecules, such as IL-10, TGF-β, and arginase1. In most tumors, the infiltrated macrophages are considered to be of the M2 phenotype, which provides an immunosuppressive microenvironment for tumor growth. Furthermore, tumor-associated macrophages secrete many cytokines, chemokines, and proteases, which promote tumor angiogenesis, growth, metastasis, and immunosuppression. Recently, it was also found that tumor-associated macrophages interact with cancer stem cells. This interaction leads to tumorigenesis, metastasis, and drug resistance. So mediating macrophage to resist tumors is considered to be potential therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, many other neoplasms are associated with M2-like TAMs that secrete immunosuppressive cytokines that promote tumor growth and metastasis (8, 90).”
From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, TAMs induce immunosuppression via release of IL-10 and TGF-β, both of which inhibit the development of cytotoxic T cells and NK cells, and may fuel the appearance of more M2-like TAMs at the tumor site (8, 67, 90).”
From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [90]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In cancer, tumor-associated macrophages (TAMs) have been known to either promote or hinder neoplasia (8, 90).”
From Macrophage Cytokines: Involvement in Immunity and Infectious Diseases (2014) · cites this paper as [90]
In the citing paper
“In contrast, M2 macrophages (CD163) play an anti-inflammatory and pro-tumor role”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [324]
In the citing paper
“TAMs often exhibit an “M2-like” phenotype [324].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [324]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 2×
“Finally, the monocytes migrate into different tissues and replenish the populations of long-lived tissue-specific macrophages, such as alveolar macrophages and kupffer cells [2, 3].”
BackgroundThe chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534 · cited 4×
“Several studies reporting the use of “antimacrophage” approaches have primarily focused on counteracting monocyte chemokines and receptors as anticancer targets [10, 14, 36, 42].”
BackgroundInfluentialMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“, tumor necrosis factor-α (TNF-α)) [6] (Figure 1).”
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 1×
“Finally, the monocytes migrate into different tissues and replenish the populations of long-lived tissue-specific macrophages, such as alveolar macrophages and kupffer cells [2, 3].”
BackgroundNF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“Finally, M2c macrophages are induced by IL-10, transforming growth factor-β (TGF-β), or glucocorticoids (GCs) [7] (Figure 1).”
BackgroundMacrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695 · cited 7×
“M1 macrophages express a series of proinflammatory cytokines, chemokines, and effector molecules, such as IL-12, IL-23, TNF-α, iNOS and MHCI/II.”
BackgroundInfluentialInterleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372 · cited 1×
“IL-23, which is also secreted by M1 macrophages, is associated with the development and expansion of Th17 cells, which can secrete high levels of IL-17 and contribute to inflammatory autoimmune pathologies [17, 18].”
BackgroundCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“Chemokines, such as CCL17 and CCL22, can prevent the infiltration of cytotoxic T-cells but promote that of Treg and Th2 cells [38, 94].”
Background
Research works printed but not linked: 12
- 2008, Journal of Immunology, 15, 3733
- 2002, American Journal of Pathology, 161, 947, 10.1016/s0002-9440(10)64255-1 · DOI · Paper page
- 2005, Oncology Reports, 14, 425
- 1996, Journal of Immunology, 156, 73
- 1997, Journal of Immunology, 159, 770
- 1995, Journal of Immunology, 154, 1280
- 2000, Cancer Research, 60, 2632
- 1999, International Journal of Cancer, 84, 539
- 1984, Annual Review of Immunology, 2, 283, 10.1146/annurev.iy.02.040184.001435 · doi:10.1146/annurev.iy.02.040184.001435 · Paper page
- 2003, Cancer Research, 63, 8360
- 1995, Cancer Research, 55, 1499
- 2003, Cancer Research, 63, 7853
Cited by
Items 301–400 of 1,000
Nascimento, C. S., Alves, É. A. R., de Melo, C. P., Corrêa‐Oliveira, R., & Calzavara-Silva, C. E. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0255 · Cited by 52
Yang, J., Shuai, J., Siow, L., Lu, J., Sun, M., An, W., Yu, M., Wang, B., & Chen, Q. (2024) · Bone Research · doi:10.1038/s41413-023-00299-0 · Cited by 51
Macrophage Polarization in IL-10 Treatment of Particle-Induced Inflammation and Osteolysis
Jiang, J., Jia, T., Gong, W., Ning, B., Wooley, P. H., & Yang, S. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.09.006 · Cited by 53
“mouse M2 phenotype macrophages.(39) It is apparent that the increased CD163 expression and diminished iNOS after IL10 treatment support an M1/M2 phenotype shifting.”
BackgroundSelf-citationCulture supernatants of cervical cancer cells induce an M2 phenotypic profile in THP-1 macrophages
Pedraza‐Brindis, E. J., Sánchez-Reyes, K., Hernández‐Flores, G., Bravo‐Cuéllar, A., Jave‐Suárez, L. F., Aguilar‐Lemarroy, A., Gómez-Lomelí, P., López-López, B. A., & Ortiz‐Lazareno, P. C. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.07.001 · Cited by 49
Mesenchymal stem cells promote macrophage polarization toward M2b-like cells
Kudlik, G., Hegyi, B., Czibula, Á., Monostori, É., Buday, L., & Uher, F. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.08.022 · Cited by 51
Nadar, R. A., Margiotta, N., Iafisco, M., van den Beucken, J. J. J. P., Boerman, O. C., & Leeuwenburgh, S. C. G. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201601119 · Cited by 49
Elechalawar, C. K., Bhattacharya, D., Ahmed, M. T., Ravuri, H. G., Sridharan, K., Chaturbedy, P., Sinha, S. H., Jaggarapu, M. M. C. S., Narayan, K. P., Chakravarty, S., et al. (2019) · Nanoscale Advances · doi:10.1039/c9na00056a · Cited by 51
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Chuang, S. T., Conklin, B., Stein, J. B., Pan, G., & Lee, K. (2022) · Nano Convergence · doi:10.1186/s40580-022-00310-0 · Cited by 51
“In particular, TAMs, classified as M2d, represent a critical therapeutic target since they constitute the major immune cell populations in tumors and mediate immunosuppression via the secretion of IL-10 and TGF-β and coordinate with other cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (T…”
BackgroundTumor Microenvironment as a Therapeutic Target in Melanoma Treatment
Kharouf, N., Flanagan, T. W., Hassan, S.-Y., Shalaby, H., Khabaz, M., Hassan, S.-L., Megahed, M., Haïkel, Y., Santourlidis, S., & Hassan, M. (2023) · Cancers · doi:10.3390/cancers15123147 · Cited by 53
“Both macrophages and tumor cells are characterized by their potency to produce proinflammatory cytokines and inflammatory mediators and thereby sustain tumor cell proliferation and survival [215,216], immune evasion [217], angiogenesis [218,219], ECM remodeling [220,221], metastasis [222], chemoresistance [218,223], a…”
BackgroundWang, C., Wang, X., Zhang, D., Sun, X., Wu, Y., Wang, J., Li, Q., & Jiang, G. (2023) · Oncology Reports · doi:10.3892/or.2023.8627 · Cited by 50
Akilbekova, D., Philiph, R., Graham, A., & Bratlie, K. M. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35169 · Cited by 47
“The M2 phenotype includes IL-10, expressed by TAMs and tumor cells and is commonly to referred as an anti-inflammatory cytokine, which is able to inhibit type I T helper (Th1) responses.(26,27) Arginase is also one of the M2 markers, metabolizing L-arginine into ornithine and polyamines, both of which are necessary fo…”
BackgroundNonlinear plasmonic imaging techniques and their biological applications
Deka, G., Sun, C., Fujita, K., & Chu, S. (2016) · Nanophotonics · doi:10.1515/nanoph-2015-0149 · Cited by 51
“They have also argued that nanoparticles with a variety of shapes, including nanosphere, nanorods, nanoshells, and nanocages, can be internalized in macrophages for the in vivo monitoring of their dynamics in atherosclerosis and cancer [39, 158].”
BackgroundO’Neil, J. D., Ross, E. A., Ridley, M. L., Ding, Q., Tang, T., Rosner, D. R., Crowley, T., Malhi, D., Dean, J. L. E., Smallie, T., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00536-16 · Cited by 50
“The other side of the coin is that increased expression of IL-10 may contribute to pathogenesis, for example, by impairing antitumor immunity (20).”
BackgroundZhao, Y., Ge, X., Xu, X., Yu, S., Wang, J., & Sun, L. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03041-8 · Cited by 50
Efferocytosis and Its Associated Cytokines: A Light on Non-tumor and Tumor Diseases?
Lin, D., Kang, X., Shen, L. H., Tu, S., Lenahan, C., Chen, Y., Wang, X., & Shao, A. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.010 · Cited by 53
“However, they differ from non-cancer diseases, as these macrophages are further polarized to a pro-tumor M2-like phenotype, followed by an increased secretion of immunosuppressive cytokines, resulting in tumor progression.(55) From this perspective, TAM receptor-directed therapies in preclinical studies and clinical t…”
Zuo, C., Baer, J. M., Knolhoff, B. L., Belle, J. I., Liu, X., de la Lastra, A. A., Fu, C. F., Hogg, G. D., Kingston, N. L., Breden, M. A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20212062 · Cited by 51
“Aside from their immunosuppressive phenotypes, macrophages are known to promote tumor initiation, angiogenesis, local invasion, and metastatic spread (Ruffell and Coussens, 2015; Hao et al., 2012; Cassetta and Pollard, 2018).”
Solís-Martínez, R., Cancino-Marentes, M., Hernández-Flores, G., Ortiz-Lazareno, P., Mandujano-Álvarez, G., Cruz-Gálvez, C., Sierra-Díaz, E., Rodríguez-Padilla, C., Jave-Suárez, L. F., Aguilar-Lemarroy, A., et al. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.009 · Cited by 47
Luo, X., Lin, L., Hu, H., Hu, F., Lin, Y., Luo, M., Wang, L., & He, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-61679-8 · Cited by 48
Atherosclerosis and Its Related Laboratory Biomarkers
Corte, V. D., Todaro, F., Cataldi, M., & Tuttolomondo, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115546 · Cited by 50
“M1-like macrophages produce pro-inflammatory cytokines such as IL-1, IL-6, TNF-α , interleukin-12 (IL-12), interleukin-23 (IL-23), and IL-13, as well as cytotoxic molecules like reactive oxygen species and nitrogen metabolites [88].”
BackgroundFarooque, A., Afrin, F., Adhikari, J., & Dwarakanath, B. (2016) · Immunobiology · doi:10.1016/j.imbio.2015.10.009 · Cited by 44
Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages
Katara, G. K., Jaiswal, M. K., Kulshrestha, A., Kolli, B. K., Gilman‐Sachs, A., & Beaman, K. D. (2013) · Oncogene · doi:10.1038/onc.2013.532 · Cited by 47
de Oliveira, C. E., Gasparoto, T. H., Pinheiro, C. R., Amôr, N. G., Nogueira, M. R. S., Kaneno, R., Garlet, G. P., Lara, V. S., Silva, J. S., Cavassani, K. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0341 · Cited by 51
Wang, B., Li, X., Hu, W., Zhou, Y., & Din, Y. (2019) · IUBMB Life · doi:10.1002/iub.2137 · Cited by 47
“M1 macrophages play a role in promoting inflammation and tumor suppression, whereas M2 macrophages involve in inhibiting inflammation and facilitating tumorigenesis.(26,27) Evidence has shown that KCs in NAFLD are mainly of the M1 phenotype, meaning the alternative activation of macrophages (M2 type) is inhibited and…”
BackgroundVisfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages
Wang, Y., Chen, H., Lo, S. J., Chen, Y.-K., Huang, Y.-C., Hu, S. C., Hsieh, Y.-C., Hung, A. C., Hou, M., & Yuan, S. F. (2020) · Cancers · doi:10.3390/cancers12123526 · Cited by 47
Jain, S., Suklabaidya, S., Das, B., Raghav, S. K., Batra, S. K., & Senapati, S. (2015) · The Prostate · doi:10.1002/pros.22983 · Cited by 47
“At the same time, CCL2 is known to be a chemo-attractant for macrophages [27,28].”
BackgroundAguado, B. A., Hartfield, R. M., Bushnell, G. G., Decker, J. T., Azarin, S. M., Nanavati, D. M., Schipma, M. J., Rao, S. S., Oakes, R. S., Zhang, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700903 · Cited by 49
Beebe, S. J., Lassiter, B. P., & Guo, S. (2018) · Cancers · doi:10.3390/cancers10040097 · Cited by 53
“…to tumor cells, the TME also includes stromal cells from the patient, including somatic cells, endothelial cells, and cohorts of suppressor Tregs and MDSC that thwart immune functions and also interact with cancer stem cells that promote tumorigenesis, drug resistances, and metastasis [52].”
Long noncoding RNA loss in immune suppression in cancer
Hu, Q., Egranov, S. D., Lin, C., & Yang, L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107591 · Cited by 46
The tumour immune microenvironment in oesophageal cancer
Davern, M., Donlon, N. E., Power, R. F., Hayes, C., King, R., Dunne, M. R., & Reynolds, J. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01331-y · Cited by 50
“TAMs secrete IL-10, TGF-β and arginase 1 which have wellcharacterised immunosuppressive functions and include inhibition of T cell activation, differentiation, proliferation, and effector functions, as well as inhibition of T cell and NK cell cytotoxicity and promotion of Treg cell expansion.(48) In addition, TGF-β in…”
BackgroundNanomedicines Targeting Glioma Stem Cells
Sabu, A., Liu, T., Ng, S. S., Doong, R., Huang, Y., & Chiu, H. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c03538 · Cited by 47
Kambayashi, Y., Fujimura, T., Furudate, S., Asano, M., Kakizaki, A., & Aiba, S. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.199 · Cited by 45
“Moreover, CD163+ macrophages surrounding EMPD expressed both CD206 (Figure 2e) and Arg1 (Figure 2f), which suggests that these CD163+ macrophages including RANK-expressing cells are M2 macrophages (Hao et al., 2012).”
BackgroundSuwanpradid, J., Shih, M., Pontius, L. N., Yang, B., Birukova, A., Guttman‐Yassky, E., Corcoran, D. L., Que, L. G., Tighe, R. M., & MacLeod, A. S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700739 · Cited by 45
Ren, J., Hou, C., Shi, C., Lin, Z., Liao, W., & Yuan, E. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.03.003 · Cited by 46
The Formation and Therapeutic Update of Tumor-Associated Macrophages in Cervical Cancer
Wang, Q., Steger, A., Mahner, S., Jeschke, U., & Heidegger, H. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133310 · Cited by 45
“Recent studies show TAMs exhibit functions similar to those of M2-like macrophages [19].”
BackgroundHydrogels to engineer tumor microenvironments in vitro
Fernando, K., Kwang, L. G., Lim, J. T. C., & Fong, E. L. S. (2021) · Biomaterials Science · doi:10.1039/d0bm01943g · Cited by 47
Review of BCG immunotherapy for bladder cancer
Liatsos, G. D., Mariolis, I., Hadziyannis, E. S., Bamias, A., & Vassilopoulos, D. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00194-23 · Cited by 44
“The association is likely due to tumor-mediated reprogramming for an immunosuppressive microenvironment, including TGF-β and IL-10 (124).”
Braster, R., Bögels, M., Beelen, R. H. J., & van Egmond, M. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.08.011 · Cited by 47
The Multifarious Role of Microglia in Brain Metastasis
Soto, M. S., & Sibson, N. R. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00414 · Cited by 44
The Role of Ageing and Parenchymal Senescence on Macrophage Function and Fibrosis
Campbell, R., Docherty, M.-H., Ferenbach, D. A., & Mylonas, K. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.700790 · Cited by 45
“M1 macrophages generate inflammatory cytokines (89) in response to microbial infection or inflammation, such as IL-6 (90), nitric oxide (NO) (91, 92), TNF-a, IL-1b, IL-12 and IL-23 (93, 94).”
BackgroundMutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 46
The mechanism of the anticancer function of M1 macrophages and their use in the clinic
Pan, X.-Q. (2012) · 癌症:英文版 · doi:10.5732/cjc.012.10046 · Cited by 44
Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation
Ribeiro, C. M. P., & Lubamba, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010118 · Cited by 45
“Macrophages may respond to various stimuli by polarizing into different phenotypes [42].”
BackgroundIntraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer
Sakamoto, S., Kagawa, S., Kuwada, K., Ito, A., Kajioka, H., Kakiuchi, Y., Watanabe, M., Kagawa, T., Yoshida, R., Kikuchi, S., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1671760 · Cited by 47
Suzuki, S., Ichikawa, Y., Nakagawa, K., Kumamoto, T., Mori, R., Matsuyama, R., Takeda, K., Ota, M., Tanaka, K., Tamura, T., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1863-z · Cited by 42
“Roles of tumorinfiltrating Mφs and DCs in some cancers have been reported [39, 40, 45–48].”
BackgroundYakupova, E. I., Maleev, G. V., Krivtsov, A. V., & Plotnikov, E. Y. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221080130 · Cited by 42
Валерьевич, К. С., Lyamina, S., Усанова, Е. А., Manukhina, E. B., Np, L., & Malyshev, I. Y. (2015) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.895563 · Cited by 44
“At least two groups of ascitic factors participate in the macrophage reprogramming towards the M2 phenotype: first, immune factors, such as the anti-inflammatory cytokine, IL-10 secreted by EAC [42], and, second, physical and chemical factors, such as hypoxia [43] and changed pH [44], which always accompany tumor grow…”
BackgroundMonocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes
Chimal-Ramírez, G. K., Espinoza‐Sánchez, N. A., Chávez-Sanchéz, L., Arriaga‐Pizano, L., & Fuentes‐Pananá, E. M. (2016) · Journal of Immunology Research · doi:10.1155/2016/6031486 · Cited by 45
“We then analyzed two panels of markers related to M1 and M2 macrophage programs, according to previous reports [1, 18, 33–35].”
Li, S., Hao, L., Kang, Q., Cui, Y., Jiang, H., Liu, X., & Lu, J. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.05.165 · Cited by 42
Guo, F., Kong, W., Zhao, G., Cheng, Z., Ai, L., Lv, J., Feng, Y., & Ma, X. (2021) · Bioscience Reports · doi:10.1042/bsr20203145 · Cited by 42
“For the mixed phenotype of macrophages in the microenvironment, recent studies have shown that TAMs have functions similar to those of M2-like macrophages [36].”
Pileri, A., Guglielmo, A., Grandi, V., Violetti, S. A., Fanoni, D., Fava, P., Agostinelli, C., Berti, E., Quaglino, P., & Pimpinelli, N. (2021) · Cells · doi:10.3390/cells10102780 · Cited by 47
“Pharmacological drugs such as thalidomide, lenalidomide, pentoxifylline, and genistein are able to inhibit macrophage infiltration and reduce the tumor’s size, while other drugs can work against macrophage-induced angiogenesis, such as anti-VEGF-A and avastin/bevacizumab [64].”
BackgroundInfluentialCell division in tissues enables macrophage infiltration
Akhmanova, M., Emtenani, S., Krueger, D., Gyoergy, A., Guarda, M., Vlasov, M., Vlasov, F., Akopian, A., Ratheesh, A., Renzis, S. D., et al. (2022) · Science · doi:10.1126/science.abj0425 · Cited by 42
Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment
Wang, D., Han, Y., Peng, L., Huang, T., He, X., Wang, J., & Ou, C. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79651 · Cited by 41
“TAM can also secrete basic FGF, VEGF, CXCL8, and other factors that promote tumor angiogenesis [41].”
BackgroundGolmohammadi, M., Zamanian, M. Y., Al‐Ani, A. M., Jabbar, T. L., Kareem, A. K., Aghaei, Z. H., Tahernia, H., Hjazi, A. M., Jissir, S. A.-R., & Hakimizadeh, E. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12491 · Cited by 42
Pahk, K., Rhee, S., Kim, S., & Choe, J. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148776 · Cited by 41
Vella, V., Francesco, E. M. D., Lappano, R., Muoio, M. G., Manzella, L., Maggiolini, M., & Belfiore, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608412 · Cited by 43
“Soluble factors present in the TME, such as IGFs, may recruit and influence macrophage behavior (Hao et al., 2012).”
BackgroundNarla, R. K., Modi, H., Bauer, D., Abbasian, M., Leisten, J. C., Piccotti, J. R., Kopytek, S., Eckelman, B. P., Deveraux, Q. L., Timmer, J. C., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03010-6 · Cited by 43
IL-1β in breast cancer bone metastasis
Zhou, J., Tulotta, C., & Ottewell, P. D. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.4 · Cited by 41
ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion
Gnosa, S. P., Blasco, L. P., Piotrowski, K. B., Freiberg, M. L., Savickas, S., Madsen, D. H., Keller, U. A. D., Kronqvist, P., & Kveiborg, M. (2022) · JCI Insight · doi:10.1172/jci.insight.155296 · Cited by 44
“They have a high capacity to adapt to external signals, and cancer cells often release factors to hijack macrophages to support tumor progression (38).”
BackgroundThe role of the tumour microenvironment in the angiogenesis of pituitary tumours
Marques, P., Barry, S., Carlsen, E., Collier, D., Ronaldson, A., Dorward, N., Grieve, J., Mendoza, N., Nair, R., Muquit, S., et al. (2020) · Endocrine · doi:10.1007/s12020-020-02478-z · Cited by 41
“In our study, PitNET microvessel area correlated positively with the M2:M1 macrophage ratio, which together with data from a recent study showing more M2-like macrophages in rat prolactinomas than in NP, and that tumour M2-like macrophage content increase as capillaries became more tortuous and of increased calibre [4…”
ResultFactor XIII-A in Diseases: Role Beyond Blood Coagulation
Dull, K., Fazekas, F., & Törőcsik, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031459 · Cited by 40
Zhang, J., Gao, J., Cui, J., Wang, Y., Jin, Y., Zhang, D., Lin, D., & Lin, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026898 · Cited by 41
“Scavenger receptor (SR), mannose receptor (MR), low MHC class II complex, and ARG1 are used as M2 phenotype markers (5).”
BackgroundMethodClinical significance of macrophage phenotypes in cardiovascular disease
Medbury, H. J., Williams, H., & Fletcher, J. (2014) · Clinical and Translational Medicine · doi:10.1186/s40169-014-0042-1 · Cited by 44
“Common markers used to identify the macrophage subsets include CD86 for M1 (as well as Arginase (Arg) II in mice) and CD163 plus CD206 (mannose receptor: MR) for M2 (as well as Arg I and FIZZ1 in mice) [15,24,27,31,46,47].”
BackgroundPPARβ/δ selectively regulates phenotypic features of age-related macular degeneration
Choudhary, M., Ding, J.-D., Qi, X., Boulton, M. E., Yao, P.-L., Peters, J. M., & Malek, G. (2016) · Aging · doi:10.18632/aging.101031 · Cited by 39
Chen, Z., Zhu, B., Chen, Z., Cao, W., Wang, J., Li, S., & Zhao, J. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00650-3 · Cited by 39
“Immunostimulatory activity of PCP Macrophages play an indispensable role in the innate and adaptive immunity of human body [42].”
BackgroundGuo, X., Zhang, H., He, C., Qin, K., Lai, Q., Fang, Y., Chen, Q., Li, W., Wang, Y., Wang, X., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00573-1 · Cited by 39
“…and IL-13, and oriented toward remodeling extracellular matrix, promoting angiogenesis, immune evasion, and promoting tumor growth and metastasis [16–23], while the M1 phenotype is induced under the influence of IFN-γ (interferon-γ), GM-CSF (granulocyte macrophage colony stimulating factor) and…”
BackgroundThapa, B., Koo, B.-S., Kim, Y. H., Kwon, H., & Kim, D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.070 · Cited by 39
Characterization and comparison of bioactive polysaccharides from the tubers of Gymnadenia conopsea
Lin, P., Wu, D., Xie, J., Zhao, J., & Li, S. (2014) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2014.05.015 · Cited by 39
Kono, Y., Kawakami, S., Higuchi, Y., Yamashita, F., & Hashida, M. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00659 · Cited by 40
Chen, S., Shao, C., Xu, M., Ji, J., Xie, Y., Lei, Y., & Wang, X. (2015) · PubMed · Cited by 39
Mulens‐Arias, V., Rojas, J. M., & Barber, D. F. (2020) · Nanomaterials · doi:10.3390/nano10050837 · Cited by 42
MicroRNAs: As Critical Regulators of Tumor- Associated Macrophages
Chatterjee, B., Saha, P., Bose, S., Shukla, D., Chatterjee, N., Kumar, S., Tripathi, P. P., & Srivastava, A. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197117 · Cited by 40
“One main feature of all M2-like macrophages is the generation of ARG-1 enzyme that reduces T-cell activation [55,114].”
BackgroundHuang, H., Chang, C., Wang, C., & Lin, K. (2021) · Cells · doi:10.3390/cells10010067 · Cited by 43
“development by producing anti-inflammatory cytokines, such as IL-4, IL-10, IL-13, and TGFβ [5], providing an immunosuppressive microenvironment that promotes tumor immune escape [6].”
BackgroundBisphosphonates and Cancer: What Opportunities from Nanotechnology?
Rosa, G. D., Misso, G., Salzano, G., & Caraglia, M. (2013) · Journal of Drug Delivery · doi:10.1155/2013/637976 · Cited by 39
“Furthermore, these tumor-associated macrophages (TAM) secrete many cytokines, chemokines, and proteases, which promote tumor angiogenesis, growth, metastasis, and immunosuppression [99].”
BackgroundWu, D., Xie, J., Wang, L., Ju, Y., Lv, G., Leong, F., Zhao, J., & Li, S. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.05.005 · Cited by 39
Song, M., Liu, T., Shi, C., Zhang, X., & Chen, X. S. (2016) · ACS Nano · doi:10.1021/acsnano.6b01206 · Cited by 39
Roles of differently polarized macrophages in the initiation and progressionof pancreatic cancer
Störz, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237711 · Cited by 39
“For example, M2 AAM restrain the inflammatory response by producing the cytokines IL-10 (5) and TGFb1 (32), but also inhibit T cell responses (83).”
BackgroundHenkels, K. M., Muppani, N. R., & Gomez-Cambronero, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166553 · Cited by 38
“NOS2 is associated with M1 macrophages and is upregulated in the tumor microenvironment of TAMs and TANs and during tumor progression [50,51].”
BackgroundZhang, Y., Zhou, N., Yu, X., Zhang, X., Li, S., Lei, Z., Hu, R., Li, H., Mao, Y., Wang, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19320 · Cited by 38
Liu, M., Sun, X., & Shi, S. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495673 · Cited by 38
MicroRNA regulated macrophage activation in obesity
Li, C., Qu, L., Farragher, C., Vella, A. T., & Zhou, B. (2019) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2019-0011 · Cited by 39
“47 JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / APR-JUN 2019 / VOL 7 |ISSUE 2 IL-1β, IL-12, and IL-23;[15,16] M2 macrophages, on the other hand, are known to secrete anti-inflammatory cytokines and growth factors, such as IL-10 and TGFβ.”
BackgroundThe Contribution of Chemoattractant GPCRs, Formylpeptide Receptors, to Inflammation and Cancer
Liang, W., Chen, K., Gong, W., Yoshimura, T., Le, Y., Wang, Y., & Wang, J. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00017 · Cited by 38
“However, with the progression of tumors, TAMs often switch to an IL-12low/IL-10high M2 phenotype with reduced tumoricidal capacity (63) but favoring tumor progression and metastasis (65, 66).”
BackgroundCancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways
Abou El Hassan, M., Huang, K., Eswara, M. B. K., Zhao, M., Song, L., Yu, T., Liu, Y., Liu, J. C., McCurdy, S., Ma, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126466 · Cited by 38
“For antibodies see S4 Table.”
BackgroundInfluentialInterleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy
Zhou, Y., Yoshida, S., Kubo, Y., Kobayashi, Y., Nakama, T., Yamaguchi, M., Ishikawa, K., Nakao, S., Ikeda, Y., Ishibashi, T., et al. (2016) · Scientific Reports · doi:10.1038/srep28140 · Cited by 38
Targeted Imaging of Tumor-Associated Macrophages by Cyanine 7-Labeled Mannose in Xenograft Tumors
Jiang, C., Cai, H., Peng, X., Zhang, P., Wu, X., & Tian, R. (2017) · Molecular Imaging · doi:10.1177/1536012116689499 · Cited by 38
“However, M2 macrophages, when activated by T-helper 2 (Th2) cytokines, promote release of vascular endothelial growth factors, which promote tumor growth and metastasis.(2,3,15) Tumor-associated macrophages have the same characteristics as M2 macrophages, including production of marginal interleukin 12 (IL-12), enhanc…”
BackgroundLiu, M., Li, Q., Wang, N., Liu, Y. ‐., Wang, L., Wang, J., Liu, M., & Zhao, Z. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105790 · Cited by 37
Lassiter, B. P., Guo, S., & Beebe, S. J. (2018) · Cancers · doi:10.3390/cancers10030069 · Cited by 40
“Tumor cell death is also promoted by death of tumor stroma tissues such as host somatic cells and macrophages, which promote tumor growth, stimulate immune suppression, and interact with cancer stem cells, contributing to tumorigenesis, drug resistance and metastasis [35].”
BackgroundTumor‐derived exosomal microRNAs and proteins as modulators of macrophage function
Moradi‐Chaleshtori, M., Hashemi, S. M., Soudi, S., Bandehpour, M., & Mohammadi‐Yeganeh, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27552 · Cited by 38
“Moreover, M1 macrophages participate in tumor‐ specific antigen presentation by overexpressing the major histocom- patibility complex class I and II molecules (Hao et al., 2012).”
BackgroundImmunotherapeutic Challenges for Pediatric Cancers
Hutzen, B. J., Ghonime, M. G., Lee, J., Mardis, E. R., Wang, R., Lee, D. A., Cairo, M. S., Roberts, R. D., Cripe, T. P., & Cassady, K. A. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.08.005 · Cited by 38
“Typically, infections stimulate the production of granulocytic MDSCs (G-MDSCs, also known as polymorphonuclear MDSCs), whereas tumors will generally stimulate the production and recruitment of myeloid MDSCs (M-MDSCs) through the secretion of a number of soluble factors.16 Both G-MDSCs and M-MDSCs produce immunosuppres…”
BackgroundXie, J., Wu, D., Li, W., Ning, C., Tang, Y., Zhao, J., & Li, S. (2017) · Journal of Food Science · doi:10.1111/1750-3841.13813 · Cited by 37
Multi-modal molecular programs regulate melanoma cell state
Andrews, M. C., Oba, J., Wu, C., Zhu, H., Karpinets, T. V., Creasy, C. A., Forget, M., Yu, X., Song, X., Mao, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31510-1 · Cited by 36
The solid tumor microenvironment and related targeting strategies: a concise review
Wang, Y., Zhou, H., Ju, S., Dong, X., & Zheng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563858 · Cited by 218
“In most tumors, in fi ltrating macrophages are dominated by M2 types, which secrete anti-in fl ammatory molecules (such as IL-10 and TGF-b ) to help shape immunosuppressive TME (158).”
Okła, K., Wertel, I., Polak, G., Surówka, J., Wawruszak, A., & Kotarski, J. (2016) · International Reviews of Immunology · doi:10.1080/08830185.2016.1206097 · Cited by 38
“Under appropriate conditions, Mφs are localized in tissue where they are capable of efficient killing of microorganisms and tumor cells [67].”
BackgroundInfluentialLee, H. Y., Hur, J., Kang, J. Y., Rhee, C. K., & Lee, S. Y. (2021) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2021.13.2.312 · Cited by 38
Parayath, N. N., Hong, B. V., Mackenzie, G. G., & Amiji, M. M. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0080 · Cited by 36
Macrophage-derived implantable vaccine prevents postsurgical tumor recurrence
Wang, D., Xue, M., Chen, J., Chen, H., Liu, J., Li, Q., Xie, Y., Hu, Y., Ni, Y., & Zhou, Q. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121161 · Cited by 36
Autophagy proteins regulate cell engulfment mechanisms that participate in cancer
Kim, S. E., & Overholtzer, M. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.05.004 · Cited by 35
“Interestingly, the continual rate of apoptosis that accompanies tumor progression may contribute to maintaining TAMs in an M2 state, as a direct result of anti-inflammatory molecules released from apoptotic cells [40-42], or as a consequence of phagocytic clearance, as macrophages ingesting apoptotic cells are known t…”
BackgroundInfluentialSinger, M., Zhang, Z., Dayyani, F., Zhang, Z., Yaghmai, V., Choi, A., Valerin, J. B., Imagawa, D. K., & Abi‐Jaoudeh, N. (2024) · Cancers · doi:10.3390/cancers17010066 · Cited by 35
“However, as tumors grow, the release of prostaglandins-E2 (PGE2) and IL-10 by cancer cells hinders the immune responses mediated by M1 proinflammatory cytokines [23].”
Self-citationYang, L., Song, X., Gong, T., Jiang, K., Hou, Y., Chen, T., Sun, X., Zhang, Z., & Gong, T. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1431979 · Cited by 35
“What is more, tumor associated macrophages (TAMs) contributed to tumor growth, angiogenesis, metastasis, immunosuppression, matrix deposition, and remodeling (Hao et al., 2012).”
BackgroundSelf-citationZhao, R., Cao, J., Yang, X., Zhang, Q., Iqbal, M. Z., Lü, J., & Kong, X. (2021) · Biomaterials Science · doi:10.1039/d1bm00508a · Cited by 36
Why Does Obesity as an Inflammatory Condition Predispose to Colorectal Cancer?
Rychter, A. M., Łykowska‐Szuber, L., Zawada, A. E., Szymczak‐Tomczak, A., Ratajczak, A. E., Skoracka, K., Kolan, M., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072451 · Cited by 39
“In most tumors, macrophages seem to be switched into the M2 phenotype, providing an immunosuppressive microenvironment and promoting tumor growth, with the obesity-affected extracellular matrix as one of the promoters [73,74].”
Background
Metadata
- Authors
- Hao, N.-B., Lü, M.-H., Fan, Y.-H., Cao, Y.-L., Zhang, Z.-R., & Yang, S.-M.
- Affiliations
- Army Medical University (CN)
- Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
- Biomedical Analysis Center, Third Military Medical University, Chongqing 40038, China
- Corresponding author
- Zhang, Zhi-Ren
- Venue
- Clinical and Developmental Immunology
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-11
- ISSN
- 1740-2522 (ISSN-L)
- 1740-2530
- PMC
- PMC3385963
- OpenAlex
- W2106027870
- Cited by
- 1,003
- References
- 121
- Citations by year
- 2026: 28 · 2025: 52 · 2024: 79 · 2023: 75 · 2022: 81 · 2021: 109 · 2020: 86 · 2019: 60 · 2018: 65 · 2017: 70 · 2016: 73 · 2015: 85 · 2014: 69 · 2013: 68 · 2012: 2
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Clinical and Developmental Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (31170851, 2010CB529406, 2009BA5045)
- National Basic Research Program of China (31170851, 2010CB529406, 2009BA5045)
- Chongqing Science Fund for Distinguished Young Scholars (31170851, 2010CB529406, 2009BA5045)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- tumor-associated macrophages, tumor microenvironment, macrophage polarization, M1 macrophages, M2 macrophages, immunosuppression, tumor angiogenesis, metastasis, cancer stem cells, drug resistance, macrophage-targeted therapy
- MeSH terms
- Animals, Humans, Macrophages, Neoplasms, Disease Progression, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.